Fischer Medical Ventures' JV Partner NYB.AI Clinches Top Global AI Innovation Award
FISCHER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fischer Medical Ventures informed exchanges that its joint venture partner, Nanyang Biologics (NYB.AI), won the 1st Prize at the inaugural SuperAI Genesis Startup Competition, selected from over 700 startups across 100+ countries. NYB.AI was recognized for its proprietary DTIGN platform, an AI-driven drug discovery tool using graph neural networks, which it claims delivers 25% higher accuracy and up to 64x improvement in hit-rate efficiency for identifying drug-target interactions, particularly in natural compounds from Southeast Asia. The company is backed by major industry partners including NVIDIA, Johnson & Johnson Innovation (JLABS), Equinix, and HPE, and has been selected to present at NVIDIA GTC 2025. Fischer Medical Ventures, as JV partner, supports NYB.AI's work on developing nutraceuticals from natural plants and herbs, and the company's Executive Chairman highlighted a breakthrough in identifying an Indian traditional herb that could aid mental health treatment.
This is a promotional/PR announcement about an award won by a JV partner rather than a direct corporate event for Fischer Medical Ventures. No new orders, revenue, financials, or regulatory approvals for the listed company are disclosed, so the immediate impact on shareholders or stock price is likely limited to sentiment and brand visibility.